Michael F Berger

80PUBLICATIONS

787CO-AUTHORS

Molecular targetsPredictive and prognostic markersEpigenetics (incl. genome methylation and epigenomics)Cancer therapy (excl. chemotherapy and radiation therapy)Cancer genetics

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (80)

Sort by Publication Date:

|Jun 26, 2026

Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer.

|Jun 24, 2026

The Genomic Landscape of MYC, MYCL, and MYCN Amplified Solid Tumors.

|Apr 22, 2026

Targeted Molecular Profiling of Circulating Cell-Free DNA in Patients With Gastroesophageal Adenocarcinoma.

|Mar 27, 2026

POLQ-driven repair scars shape the immunogenic landscape of homologous recombination-deficient pancreatic cancer.

Wungki Park, Shigeaki Umeda, Marc Hilmi

|Mar 26, 2026

Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial.

Wungki Park, Catherine A O'Connor, Joanne F Chou

|Mar 25, 2026

A Phase II Trial of Olaparib plus Pembrolizumab in Patients with Recurrent Copy Number-High/p53-Abnormal Endometrial Cancer.

Maria M Rubinstein, Jennifer Y Ge, Qin Zhou

Pageof 14

Frequent Collaborators

30 joint publications

David Solit

22 joint publications

Nikolaus Schultz

19 joint publications

Ahmet Zehir

18 joint publications

Marc Ladanyi

15 joint publications

Rose Brannon

15 joint publications

Zsofia Stadler

15 joint publications

Yelena M Kemel

14 joint publications

Diana Mandelker

14 joint publications

Chaitanya Bandlamudi

13 joint publications

Debyani Chakravarty

Frequent Collaborators

30 joint publications

David Solit

22 joint publications

Nikolaus Schultz

19 joint publications

Ahmet Zehir

18 joint publications

Marc Ladanyi